The atorvastatin metabolic phenotype shift is influenced by interaction of drug-transporter polymorphisms in Mexican population: results of a randomized trial

por León-Cachón, Rafael B. R., Bamford, Aileen-Diane, Meester, Irene, Barrera-Saldaña, Hugo Alberto, Gómez-Silva, Magdalena, Bustos, María F. García
Publicado 2020

Pharmacogenetics of amfepramone in healthy Mexican subjects reveals potential markers for tailoring pharmacotherapy of obesity: results of a randomised trial

por Gómez-Silva, Magdalena, Piñeyro-Garza, Everardo, Vargas-Zapata, Rigoberto, Gamino-Peña, María Elena, León-García, Armando, de León, Mario Bermúdez, Llerena, Adrián, León-Cachón, Rafael B. R.
Publicado 2019

A pharmacogenetic pilot study reveals MTHFR, DRD3, and MDR1 polymorphisms as biomarker candidates for slow atorvastatin metabolizers

por León-Cachón, Rafael B. R., Ascacio-Martínez, Jorge A., Gamino-Peña, María E., Cerda-Flores, Ricardo M., Meester, Irene, Gallardo-Blanco, Hugo L., Gómez-Silva, Magdalena, Piñeyro-Garza, Everardo, Barrera-Saldaña, Hugo A.
Publicado 2016